Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor (NCT04616560)
A Phase 1/2 Study of DS-8201a (NSC# 807708) in Children, Adolescents, or Young Adults With Recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
🩺 Plain-English Summary (8th-Grade Level)
This phase I/II trial studies the effects of trastuzumab deruxtecan (DS-8201a) in treating patients with osteosarcoma, Wilms tumor (WT) or desmoplastic small round cell tumor (DSRCT) that is newly diagnosed or has come back after a period of improvement (recurrent) or that has not responded to previous treatment (refractory). Trastuzumab deruxtecan is in a class of medications called antibody-drug conjugates. It is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive tumor cells in a targeted way and delivers deruxtecan to kill them.
Who can join: Review the eligibility criteria below.
Location: Children's Hospital of Alabama — Birmingham, Alabama
Age range: 12 Years to 39 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (29 Sites)
Showing the first 25 of 29 sites.
- Children's Hospital of Alabama — Birmingham, Alabama
- Children's Hospital Los Angeles — Los Angeles, California
- Children's Hospital of Orange County — Orange, California
- Lucile Packard Children's Hospital Stanford University — Palo Alto, California
- UCSF Medical Center-Mission Bay — San Francisco, California
- Children's Hospital Colorado — Aurora, Colorado
- Children's National Medical Center — Washington D.C., District of Columbia
- Johns Hopkins All Children's Hospital — St. Petersburg, Florida
- Children's Healthcare of Atlanta - Arthur M Blank Hospital — Atlanta, Georgia
- Lurie Children's Hospital-Chicago — Chicago, Illinois
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- Riley Hospital for Children — Indianapolis, Indiana
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
- Dana-Farber Cancer Institute — Boston, Massachusetts
- C S Mott Children's Hospital — Ann Arbor, Michigan
- University of Minnesota/Masonic Cancer Center — Minneapolis, Minnesota
- Children's Mercy Hospitals and Clinics — Kansas City, Missouri
- Washington University School of Medicine — St Louis, Missouri
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Duke University Medical Center — Durham, North Carolina
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania
- Saint Jude Children's Research Hospital — Memphis, Tennessee
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Desmoplastic Small Round Cell Tumor
Explore by condition: All Desmoplastic Small Round Cell Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.